Atara biotherapeutics announces preliminary results for ata2271, a next-generation autologous mesothelin-targeted car t-cell therapy for solid tumors, at esmo immuno-oncology congress 2021

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced new preclinical and preliminary clinical results for ata2271, a next-generation autologous chimeric antigen receptor (car) t-cell therapy targeting mesothelin (msln). these promising early safety and
ATRA Ratings Summary
ATRA Quant Ranking